IKIryna V. Kruchok

Iryna V. Kruchok

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Iryna V. Kruchok has a total of 30 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Adjuvant antiangiogenic targeted therapy in the radiosurgical treatment of recurrent cerebral metastases

    by О.YA. Glavatskyi, A.B. Griazov, I.V. Kruchok, H.V. Khmelnytskyi, L.P. Yakovenko, O.V. Zemskova, О.я. Главацький, Г.в. Хмельницький

    Background. Stereotactic radiosurgery (SRS) is a standard treatment method for patients with primary brain metastases regardless of their tumor nosology. At the same time, there are not any standard treatment methods for recurrent brain metastases, which have a significantly worse prognosis. Our own experience and literature data indicate that the combination of radiation therapy and antiangiogenic targeted drug bevacizumab (BEV) improves treatment results in both primary malignant and metastatic tumors of the brain. Purpose – to assess the efficacy and safety of BEV in repeated radiosurgery of recurrent brain metastases after high-dose radiation therapy. Materials and methods. The prospective unicentral nonrandomized study was conducted in the State Institution «Romodanov Neurosurgery Institute of the National Academy of Medical Sciences of Ukraine» (2017–2024). It involved a sample of 16 patients with recurrent brain metastases of the most common tumor nosologies to the brain. The patients previously received high-dose radiosurgical treatment for primary brain metastases. In cases of metastatic recurrence, both single-fraction and multi-fraction radiosurgery were used. They were performed using the Trilogy linear accelerator with bremsstrahlung energy of 6 MeV. The dose ranged from 15 to 22.5 Gy. BEV was used as an adjuvant drug in all patients after radiation therapy to decrease symptoms of radiotoxicity and worsening of quality of life caused by it. The patients received from 2 to 18 courses of BEV at a dose of 10 mg/kg of weight with an interval of 3 weeks. We conducted an overall survival analysis of patients who received BEV after radiosurgical treatment of recurrent brain metastases. Results. The time of development of recurrent brain metastases after the first high-dose SRS ranged from 7 to 18 months with a median survival of 12 months. The patients were receiving radiosurgical treatment for recurrent brain metastases in combination with BEV from May 2019 to December 2023. One-year overall survival was 68.7% with a median of 21 months, which surpassed the median survival after the first radiosurgery by 9 months. The neurological deficit fully regressed in 9 patients (56.3%). In other patients, significant neurological improvement was achieved. At the time of analysis, 8 patients were still followed up. The use of BEV in patients with brain metastases after radiosurgical treatment demonstrated an acceptable toxicity profile. According to CTCAE v5.0, no cases of grade 3–5 adverse events were registered. MRI imaging over the course of time showed a positive response in terms of achieving local control in 87.6% of cases. Conclusions. The use of BEV allows toxic symptoms of repeated radiosurgical treatment to be minimized and the duration and quality of life of patients to be improved. The clinical effect was supported by a clear radiological response according to the MRI imaging data.

  • Open Access

    The analysis of quality of life of patients with glioblastoma after adjuvant radiation therapy

    by O.Ya. Glavatskyi, A.B. Gryazov, O.Yu. Chuvashova, I.V. Kruchok, H.V. Khmelnytskyi, V.P. Starenkyi, V.A. Stuley, O.V. Zemskova

    Background. Optimizing approaches to the treatment of patients with glioblastoma (GB) is an urgent task partly owing to the wider implementation of hypofractionated radiation therapy (HRT) regimens. At the same time, increasing survival without maintaining the patient’s quality of life (QoL) cannot be considered successful treatment. Purpose – to analyze QoL of patients with GB after adjuvant radiation treatment in the groups of standard and hypofractionated radiation regimens. Materials and methods. 159 patients with verified GB, who had undergone surgery in State Institution «Romodanov Neurosurgery Institute of the National Academy of Medical Sciences of Ukraine» over the period from 2014 to 2020, were divided into two groups according to the regimen of RT: SRT group (n = 49) – standard regimen (total dose 60.0 Gy in 30 fractions over 6 weeks); HRT group (n = 110) – hypofractionated regimen (total dose 52.5 Gy in 15 fractions over 3 weeks). The patients were surveyed about QoL three times during their follow-up (3, 6 and 12 months after RT) according to the Global Health Status Scale (GHSS), domains of insomnia and fatigue of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core-30 (QLQ-C30 version 3.0). Statistical analysis was performed separately for each group (SRT and HRT; intragroup analysis), as well as between SRT and HRT groups as comparison of independent groups with a different number of follow-up examinations for each period of the follow-up (intergroup analysis). Results. The H0 hypothesis about the absence of statistically significant difference between the results of three subsequent surveys according to the GHSS, domains of insomnia and fatigue in both SRT (p = 0.00003; p = 0.00002; p = 0.00002, respectively) and HRT (p = 0.00000; p = 0.00001; p = 0.00001, respectively) groups in the intragroup analysis according to the Friedman test was rejected. The pairwise comparison of the results of the second and the first survey (6 vs. 3 months) according to the Wilcoxon test showed a statistically significant decrease in QoL in the domain of insomnia (р = 0.000733) in SRT group and in the domain of fatigue (р = 0.016813) in HRT group. When comparing the results of the third and the second survey (12 vs. 6 months), the H0 hypothesis for all the studied parameters of QoL (GHS, insomnia, and fatigue) was rejected in both SRT and HRT groups (p ≤ 0.017 with the Bonferroni correction). When comparing the results of the third and the first survey (12 vs. 3 months), a statistically significant decrease in QoL in all studied parameters of QoL was observed: GHSS (р = 0.000078); fatigue (р = 0.000294); insomnia (р = 0.000318). The comparison of the results of these surveys in SRT group showed a statistically significant decrease of QoL in GHSS (р = 0.004650) and fatigue (p = 0.017938), with the level of statistical significance getting closer to the set critical value considering the Bonferroni correction. The intergroup analysis according to the Mann-Whitney U test showed a statistically significant advantage of HRT over SRT in all studied parameters of QoL in three subsequent surveys (p < 0.05). The ρ-test confirmed these data: HRT group patients had better parameters of QoL than SRT group patients over the whole period of the follow-up. Conclusions. The analysis of QoL according to the results of three subsequent surveys 3, 6, and 12 months after RT according to the GHSS, domains of insomnia and fatigue of the EORTC QLQ-C30 demonstrated a decrease in QoL of patients in both SRT and HRT groups. At the same time, a statistically significant advantage of HRT group over SRT group in all studied parameters of SRT was observed when the results of three subsequent surveys were compared. The proposed regimen of HRT for patients with primarily diagnosed GB may be considered an acceptable alternative to SRT in view of impact on QoL.

  • Open Access

    Vestibular Schwannomas: implementation of PANQOL and Mayo VSQOL Index scales in Ukraine and justification of treatment strategy with preservation of quality of life (problem analysis, own experience, discussion points)

    by Volodymyr O. Fedirko, Mykola V. Yehorov, Olga Y. Chuvashova, Tetiana A. Malysheva, Oleg M. Borysenko, Vasyl V. Shust, Dmytro M. Tsiurupa, Petro M. Onishchenko, Artem V. Rozumenko, Iryna V. Kruchok, et al.

    Objective: To evaluate the treatment outcomes of sporadic vestibular schwannomas (VS) to substantiate the choice of optimal treatment strategy considering quality of life indicators using the Penn Acoustic Neuroma Quality of Life Scale (PANQOL) and the Mayo Clinic Vestibular Schwannoma Quality of Life Index (Mayo VSQOL Index) scales in Ukraine. Materials and Methods: 1100 patients with VS were treated at the Subtentorial Neurooncology Department from 2001 to October 2023 and 373 were primarily considered for dynamic observation (“wait-and-scan”) at the Department of Ear Microsurgery and Otoneurosurgery of the Kolomiichenko Otolaryngology Institute. Data on 359 patients (some of whom underwent surgery in the mentioned departments) who received radiotherapy (RT) from 2010 to 2023 in the Radioneurosurgery Department are also provided. The PANQOL and Mayo VSQOL Index scales were implemented to assess the quality of life of patients with VS. Scientific publications from the PubMed database related to the study of the quality of life in patients with VS were analyzed. Results: The analysis was based on patient data from the database for the period 2017 - October 2023, 391 patients with VS were treated, including 359 who underwent surgical treatment (schwannomas resection), 4 – tarsorrhaphy after VS resection, and 28 who received combined treatment (surgery + radiotherapy). A separate group consisted of 359 patients who underwent radiotherapy (RT). Of 177 patients who underwent radiosurgical treatment, 65 (36.7%) had Stage III VS according to the classification of W.T. Koos, and 112 (63.3%) had stage IV VS. Primarily diagnosed tumors were treated in 110 (62.1%) and 67(37.9%) patients with residual postoperative. Follow-up data were obtained for 159 patients. At the Kolomiichenko Otolaryngology Institute, 373 patients were under observation with the primary "wait-and-scan" strategy, of whom 110 (29.5%) had their VS removed due to symptom progression or progressive course, and 24 (6.4%) underwent RT. Of the 27 patients in the Subtentorial Neurooncology Department study group, 7 (25.9%) underwent surgery, and 5 (18.5%) underwent RT. Conclusions: Global practice in assisting patients with VS indicates a shift towards dynamic follow-up and an increase in the frequency of using radiation treatment methods. Over the past years, strategy have been proposed that do not recommend the "wait-and-scan" mode due to the risk of life-threatening complications associated with tumor growth. However, there is very little data on long-term outcomes (more than 5 years) and quality of life. VS primarily detected by magnetic resonance imaging in Ukraine significantly larger (Koos III-IV) than those reported in the literature. The implementation of specialized scales for assessing the quality of life of VS patients in Ukraine will help improve outcomes by applying personalized criteria for treatment routes, increasing the level of awareness and responsibility of both patients and doctors.


  • Open Access

    Glioblastoma: quality of life as a key element in evaluation of radiation treatment effectiveness

    by O.Ya. Glavatskyi, A.B. Gryazov, O.Yu. Chuvashova, I.V. Kruchok, В.п. Старенький, V.S. Ivankova, В.в. Талько, A.M. Nasonova, О.я. Главацький

    Background. Along with the traditional assessment of oncological outcomes with a focus on survival, information about the patient’s quality of life (QOL) plays a key role in evaluating the effectiveness of treatment. The QOL assessment reflecting a person’s subjective perception of their situation in the disease context is now considered a tool for changing the current paradigm of therapeutic effectiveness, including that in neuro-oncology. Modern high-tech radiation therapy offers wide possibilities for modifying radiation regimens, in particularly, by means of hypofractionation. Given the considerable clinical benefits of the latter, there is a growing interest in studies that include QOL assessment along with conventional biomedical outcomes, particularly in patients with glioblastoma. Purpose. This analytical review focuses on the clinical aspects of QOL assessment in the context of radiation treatment of glioblastoma patients, beyond the discussion of oncological outcomes. Materials and methods. References were analyzed using English-language biomedical databases (MEDLINE (Pubmed), EMBASE (Ovid), Web of Science (Web of Knowledge) using the following Keywords: «Quality of life», «Health-related quality of life», «Radiation Therapy», «Hypofractionated radiotherapy», «Hypofractionated irradiation», «CNS tumors», «Brain tumors», «Glioblastoma». When analyzing all sources, backlinks were made to the original sources to identify the additional relevant studies. The last date of the search was February 01, 2024. Results. Nowadays, QOL assessment is broadly integrated into the neuro-oncology practice. This analysis is used for the comprehensive treatment outcome assessment in various clinical scenarios, including modification of radiation therapy regimens. The results of cancer treatment are not considered satisfactory if the survival is not associated with the maintenance of QOL. The main tool for QOL assessment is the EORTC QLQ-C30 questionnaire; for patients with brain tumors, there is an additional specific module BN-20. QOL analysis demonstrates the benefits of hypofractionated radiation therapy for glioblastoma patients, as a reduced radiation course has a favorable impact on QOL, without significant difference in toxicity and expected survival compared to standard regimens. The QOL study proves the positive effect of combining adjuvant radiation therapy and neurorehabilitation for glioblastoma patients using virtual reality technology. It has been established that QOL remains stable following re-irradiation of patients with recurrent gliomas. QOL analysis provides the opportunities to reveal the medical and social aspects of neuro-oncological diseases and demonstrates the burden of the disease not only for the person directly affected by glioblastoma, but also for those who care for the patient. The number of publications dedicated to the QOL assessment in proton radiation therapy is growing. Conclusion. If there is no significant difference between the toxicity of treatments (including radiation) and expected survival, QOL can serve as a criterion for an optimal therapy selection. QOL analysis is used for the comprehensive treatment outcome assessment in various clinical scenarios, including modification of radiation therapy regimens (e.g., hypofractionation). QOL analysis is complex and requires unification. Acquiring the methodology of QOL assessment is a necessary requirement for researchers involved in modern neuro-oncology studies. Актуальність. Поряд з традиційною оцінкою онкологічних результатів з фокусом на виживаності, інформація про якість життя (ЯЖ) пацієнта відіграє ключову роль у визначенні успішності лікування. Оцінка ЯЖ, що є відображенням суб’єктивного сприйняття людиною свого становища в контексті певного захворювання, розглядається сьогодні як інструмент зміни сучасної парадигми терапевтичної ефективності, зокрема, в нейроонкології. Сучасна високотехнологічна променева терапія має широкі можливості щодо модифікації режимів опромінення за рахунок гіпофракціонування. Враховуючи суттєві клінічні переваги останніх, зростає інтерес до досліджень, що включають оцінку ЯЖ поряд із загальноприйнятими біомедичними результатами, зокрема, у пацієнтів з гліобластомою. Мета роботи – аналітичний огляд, що сфокусований на клінічних аспектах оцінки ЯЖ у ході променевого лікування пацієнтів з гліобластомою, поза межами обговорення онкологічних результатів. Матеріали та методи. Літературні джерела проаналізовані за допомогою англомовних текстових баз біомедичних метаданих (MEDLINE (Pubmed), EMBASE (Ovid), Web of Science (Web of Knowledge) за пошуковими ключовими словами «Quality of life», «Health-related quality of life», «Radiation Therapy», «Hypofractionated radiotherapy», «Hypofractionated irradiation», «CNS tumors», «Brain tumors», «Glioblastoma». При аналізі всіх джерел були зроблені зворотні посилання на першоджерела для виявлення...

  • Open Access

    Aspects of hypofractionation in modern radiation oncology

    by A.B. Gryazov, O. Ya. Glavatskyi, O.Yu. Chuvashova, I.V. Kruchok, A.A. Griazov, В.п. Старенький, H.V. Kulinich, F.V. Hladkykh, O.V. Zemskova

    Background. In the modern world, the incidence of cancer diseases is rapidly increasing and is the second most common cause of death. This is preconditioned by the quantitative growth of the senior and elderly population, as well as the growth of the main risk factors for cancer, which is related to the socio-economic development of society. About half of cancer cases require radiation therapy (RT) as a component of multimodal treatment, therefore its improvement, namely the introduction of hypofractionated radiation regimens, is considered today as one of the most effective ways to increase availability of oncological care and optimize the use of health care system resources. Purpose. To find out clinical and medico-social advantages of the hypofractionated approach in radiation oncology in order to optimize the functioning of the health care system by increasing availability of treatment for cancer patients. To highlight the importance of hypofractionated RT in terms of evidence-based medicine for the most common oncological pathology and in neuro-oncology. To demonstrate the influence of the COVID-19 pandemic on the implementation of hypofractionated RT. To present our own experience of using hypofractionated radiation regimens in patients with glioblastoma (GB). Materials and methods. MEDLINE (Pubmed), EMBASE (Ovid), Web of Science (Web of Knowledge) databases were used to search for literature. The search was performed in the English-language sources with the following keywords: «Radiation», «Hypofractionation radiotherapy», «Hypofractionated radiotherapy», «Hypofractionated irradiation»; «Breast cancer»; «Prostate cancer»; «Lung cancer»; «Glioblastoma», COVID-19. Systematic reviews, meta-analyses, randomized controlled trials and retrospective clinical trials were reviewed in full. The primary sources were backreferenced to identify additional relevant studies related to hypofractionated radiation treatment regimens. The last date of the search is 05.25.2023. The authors’ own experience of the hypofractionated approach in the adjuvant radiation treatment of patients with GB is presented briefly, as a reflection of the relevance of the authors’ practical experience to the provisions of the narrative review, based on the results of a retrospective single-center non-randomized study conducted at the State Institution «Romodanov Neurosurgery Institute National Academy of Medical Sciences of Ukraine» in 2014–2020. The oncological results of 110 (69.2%) patients of the hypofractionated RT group (15 fractions, single fraction dose (SFD) 3.5 Gy, total fraction dose (TFD) 52.5 Gy) and 49 (30.8%) patients of the standard RT group (30 fractions, RVD 2.0 Gy, SVD 60.0 Gy) were compared. RT was performed with Trilogy linear accelerator (USA) (6 MeV) using the intensity-modulated radiotherapy method (IMRT). Overall survival (OS) and recurrence-free survival (RFS) in the groups were analyzed. Results and discussion. Hypofractionated approaches, which allow to significantly decrease the duration of radiation treatment, have clinical, medical and social advantages, including: increased comfort for a patient; reduction of the workload on staff and technological equipment of medical facilities; reduction of the cost of treatment. The introduction of hypofractionated RT allows to increase access to cancer care at the global level, reducing disparity in the results of treatment of cancer patients between low- and middle-income countries and the countries with high income level. Hypofractionated radiation regimens are included in the clinical guidelines of professional associations, as for the most common forms of cancer and for malignant brain tumors, and represent the standard of treatment for particular clinical cases. Our experience of using the hypofractionated radiation regimen is based on the adjuvant radiation treatment of 110 patients with GB and in terms of clinical results is a relevant concept presented in a narrative review. The analysis showed no statistical difference between the groups of standard fractionation and hypofractionated RT in OS (Logrank test p = 0.06757) and RFS (Logrank test p = 0.43374). In the hypofractionation group, with an observation time median of 22.3 months, the OS median was 16.5 (95% CI 14.1–18.8) months; median RFS was 9.0 (95% CI 8.0–10.0) months. In the standard radiation regimen group, with a median of observation time of 24.4 months, the median OS was 15.0 (95% CI 14.1–17.1) months; median RFS is 9.0 (95% CI 9.0–10.0) months. Conclusion. Development and implementation of the measures designed to optimize the use of resources of medical facilities of Ukraine is a necessary condition for maintaining high-quality care for cancer patients in the conditions of full-scale military aggression, which has been ongoing since February 24, 2022. Increased application of hypofractionated approaches in radiation oncology can be considered as a potential tool for optimization of the use of resources of the healthcare system of Ukraine and enhancing public health. Актуальність. В сучасному світі частота онкологічних захворювань стрімко зростає і є другою за поширеністю причиною смерті. Це зумовлено як кількісним зростанням населення старшого та похилого віку, так і зростанням основних факторів ризику раку, що пов’язано з соціально-економічним розвитком суспільства. Близько половини випадків онкозахворювань потребують променевої терапії (ПТ) як складової мультимодального лікування, тому її удосконалення, а саме впровадження...


  • Open Access

    Hypofractionated radiotherapy of patients with glioblastoma: the first experience in Ukraine and prospects view

    by Andrey B. Gryazov, Oleksandr Y. Glavatskyi, Olga Y. Chuvashova, Oksana V. Zemskova, Olena G. Andriichenko, Iryna V. Kruchok, Andrii A. Griazov, Igor P. Spasichenko, Hennadii V. Khmelnytskyi, Iryna M. Shuba, et al.

    Objective: To assess the survival of patients (pts) with newly diagnosed glioblastoma (GBM) in groups with hypofractionated regime radiotherapy, standard fractionationated regime radiotherapy and whole brain irradiation. Materials and methods: A retrospective non-randomized single-center study of 205 pts with GBM grade 4 according to the WHO classification treated in Romodanov Neurosurgery Institute named after Acad. A.P. Romodanov National Academy of Medical Science of Ukraine (2014–2020). The mean age of pts 53.8 years (95% CI 52.1 - 55.5); there were 114 men (55.6%) and 91 women (44.4%). According to the regimen radiotherapy (RT), pts were divided into 3 groups: 49 (23.9%) pts (standard RT: 2.0 Gy per fraction in 30 fractions, total dose 60.0 Gy) – group "sRT", 110 (53.7%) pts (hypofractionated RT: 3.5 Gy per fraction in 15 fractions, total dose 52, 5 Gy) - group "hRT", 46 (22.4%) pts – group "WBRT" (whole brain radiation). Differences in progression-free survival (PFS) and overall survival (OS) between the three groups were analyzed using Kaplan–Meier survival curve, log-rank test and Pearson Chi-square test. Results: The median OS is 15,0 (95% CI 14,1 – 17,1), 16,5 (95% CI 14,1 – 18,8) and 8,7 (95% CІ 7,5 – 9,5) months for sRT, hRT and WBRT, respectively. There is a significant difference in OS for sRT and hRT compared to WBRT (p=0.00000), without difference in OS between sRT and hRT (p=0.06757). The median PFS in sRT and hRT does not differ significantly: sRT – 9.0 (95% CI 9.0 - 10.0) months; hRT – 9.0 (95% CI 8.0 - 10.0) months. The median OS for WBRT is 5.1 (95% CI 4.0 - 6.0) months. There is a significant difference in PFS for sRT and hRT compared to the WBRT (p=0.00000), without difference in PFS between sRT and hRT (p=0.43374). The risk of death for WBRT compared to sRT is 2.5 times higher (HR 2.5 [95% CI, 1.45 - 4.46)) and 3.5 times higher compared to the hRT group (HR 3.5 [95% CI, 2.09-5.88)). The risk of progression for WBRT is 2.8 times higher (HR 2.78 [95% CI, 1.63-4.74)) compared to sRT, and 3.1 times higher (HR 3.12 [95% CI, 1.91-5.10)) compared to hRT. The broad implementation of hRT into clinical practice is specific to all modern radiation oncology. This trend is currently underway due to the specific positive clinical effects of hRT, which are discussed in detail in our publication. Conclusions: Our study demonstrates comparable survival outcome between sRT and hRT groups. This is an argument in favor of the feasibility of using hRT as a part of multimodal GBM treatment in terms of oncological outcomes. Further studies are needed to identify specific stratification groups of GMB patients with the greatest survival and quality of life benefits due to hRT.


  • Open Access

    Survival after stereotactic radiosurgery of recurrent glioblastomas in patients with radical resection of primary tumor

    by Andrii Griazov, Oleksandr Glavatskyi, Oksana Zemskova, Andrey Gryazov, Olga Chuvashova, Hennadii Khmelnytskyi, Iryna Shuba, Iryna Kruchok, Maksim Shevelov, Volodymyr Stuley

    гліобластома (ГБ) – це агресивна пухлина, що характеризується високим рівнем рецидивування та призводить до смерті більшості хворих через 15–18 місяців після встановлення діагнозу. Факторами, що асоціюються з більш тривалою виживаністю хворих на ГБ, є вік до 50 років, кращий функціональний статус та радикальна резекція первинної пухлини. Оптимальне лікування при рецидиві або прогресуванні ГБ до цього часу не визначено та залишається складною проблемою. Стереотаксична радіохірургія (СРХ) є методом прецизійного високотехнологічного опромінення, що розглядається сьогодні як терапевтична опція ефективного впливу на рецидивні злоякісні гліоми. Метою даного ретроспективного дослідження був аналіз виживаності після СРХ рецидивної ГБ в когорті 59 хворих, яким було проведено радикальну резекцію первинної пухлини. Досліджувана когорта складалась з 59 хворих (28 / 47,5% жінок та 31 / 52,5% чоловіків); середній вік в загальній групі склав 51 рік (інтервал 24 – 81). СРХ проводилось на лінійному прискорювачі «Trilogy» (США) (6 MeV) в період з 2014 р. по 2020 р. в Державній установі «Інститут нейрохірургії ім. акад. А.П. Ромоданова НАМН України». В усіх випадках діагноз ГБ 4 ступеню за класифікацією ВООЗ був підтверджений патоморфологічно після резекції первинної пухлини. Всім 59 хворим було проведено максимальне безпечне видалення первинної пухлини в радикальному об’ємі: в переважній кількості спостережень (54 / 91,5%) – по перифокальній зоні; в 5 / 8,5% випадках – субтотально. В усіх 59 випадках хворим було проведено ад’ювантне променеве лікування після видалення первинної пухлини (сумарна вогнищева доза (СВД) 60 Гр, 30 фракцій), яке в 33 випадках було поєднане з алкілюючою ХТ (темозоломід 75 мг/м2). У 31 / 52,5 % хворого після завершення конкомітантної ХТ продовжилось ХТ лікування (темозоломід 150-200 мг/ м2). У більшості спостережень (51 / 86,4 %) РГБ було діагностовано за сукупністю клініко-радіологічних ознак; у 8 / 13,6 % хворих – патоморфологічно, після повторного хірургічного втручання. Кінцевими точками дослідження були загальна виживаність (ЗВ), безрецидивна (безпрогресивна) виживаність (БРВ) та виживаність після настання рецидиву (ВПР). Вивчався вплив на виживаність наступних кількісних та категоріальних факторів: стать, вік, функціональний статус, поєднання ад’ювантної ПТ з алкілюючою ХТ, хірургічне видалення РГБ, тип рецидивування ГБ, дозове навантаження за всі курси опромінення сумарно (за біологічно-ефективною дозою (BED11)) та при СРХ, кількість фракцій СРХ, об’єм мішені СРХ, термін безрецидивного періоду/виживаності (БРВ). Вплив на виживаність такого фактору як БРВ досліджувався шляхом розподілення когорти на три незалежні групи в залежності від тривалості безрецидивного періоду: група I – БРВ < 10 місяців; група II – БРВ від 10 до 20 місяців; група III – БРВ > 20 місяців. Виживаність хворих була проаналізована методом Каплана-Майера (КМ). Логарифмічний ранговий тест (для порівняння КМ кривих виживаності для різних досліджуваних груп) використовували для дослідження виживаності за бінарними предикторами. Порівняння впливу декількох категоріальних факторів на виживаність здійснювалось за допомогою χ2-тесту (Pearson Chi-square test). Для дослідження впливу на виживаність кількісних коваріат використовували регресійний аналіз за моделлю пропорційних ризиків...